Physician profile
Eva Doyle Markward
NPI 1801891601
$2,646.68
in general payments reported to CMS, 2019-2025
18 companies · $603 in 2025
The $603 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $72.90 · 2021: $230 · 2022: $496 · 2023: $381 · 2024: $527 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $786.77 | 2022-2025 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $462.61 | 2020-2025 | Precision 1, Precision7, Dailies Total1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $325.72 | 2019-2021 | |
| Visionix USA, INC | $140.00 | 2022 | |
| Lkc Technologies, INC. | $131.75 | 2024-2025 | |
| Biotissue Holdings INC. | $128.85 | 2019-2024 | |
| Oyster Point Pharma, INC. | $125.00 | 2023 | Tyrvaya |
| Abbvie INC. | $100.00 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $96.15 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $95.54 | 2022 | |
| Sight Sciences, INC. | $94.72 | 2025 | Tearcare System |
| Shire North American Group INC | $46.95 | 2019 | |
| Visioneering Technologies, INC. | $26.15 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.51 | 2019 | |
| Dompe US, INC. | $18.85 | 2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $17.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.75 | 2020 | |
| Coopervision INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Markward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.